Adenosine Deaminase Activity in Diabetic and Obese Patients.

Adenosine deaminase (ADA) commonly associated with severe combined immunodeficiency disease believed to be an important enzyme for the modulation of bioactivity of insulin. The clinical significance in Metabolic Diseases patients in South Eastern Nigeria was studied. Body Mass Index (BMI), Fating Blood Glucose, Glycated Heamoglobin (GHbA1C), total serum Adenosine Deaminase (ADA) activities were measured apparently healthy people (control), (n =25), type II diabetic patients, n = 25), obese patients ( obese diabetics n = 25), obese non-diabetics n = 25, non –obese diabetic n = 25), respectively. The results (mean±) show that the mean values in the test groups were significantly higher than the controls respectively. . FBG in obese-diabetic (12.5±2mmol/L) and non-obese – diabetic (4.8±0.4mmol/l) 0 differed statistically (p<0.05) except in obese non- diabetic (11.3± 1.3mmol/L), (p<0.05). GHbA1C differed significantly in obeses diabetic (17.35±1.5%), obese non-diabetic (12.87±0.6%) and non-obese diabetic (14.2±0.75%) patients (p. <001) respectively. ADA activities also differed in obese diabetics (22.88±2.65iu/L), obese non-diabetics, (18.23.±0.872iu/l), and obese nondiabetics (18.076±1.4 p<0.001) respectively while. BMI showed no correlation with FBG, GHbA1C, and ADA respectively. Comparatavely adenosine deaminase, assays are cost effective –method that could be employed in the daily routine laboratories during investigation and treatment of metabolic diseases, especially obesities and diabetic patients. Key Words : Diabetes mellitus, Adenosine deaminase, Metabolic Syndrome